However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...

The group’s $63 billion acquisition of Roundup weed killer parent Monsanto in 2018 has proved disastrous for Bayer, as it faced wave after wave of lawsuits over claims the product contributed to ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Bayer pharma chief sees no big acquisitions in near ... of some long-running mass tort litigation based on traditional product liability theories of toxic exposure, and potentially the rise ...

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

The German pharma company ... of the weedkiller product. Sales of Roundup, one of the most widely used weedkillers in the US, ...

Bayer's venerable testosterone replacement ... The group is facing the threat of competition from big-selling pharma products Eylea (aflibercept) for ophthalmic diseases and anticoagulant Xarelto ...

“Rather than a lumbering corporation, Bayer will emerge as agile ... Another example: the company’s pharma division, based in Italy, has cut product release times by 50%.

Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...

Due to its extensive range of services, professional consulting and high-quality technologically advanced products, ViscoTec ...